| Abstract: | Recombination of genetic material enables the creation of new bacterial strains which can synthesize specific proteins in large amounts. Such bacteria permit the production of previously inaccessible proteins. They can therefore be used as starting materials for the production of drugs which will open up new paths for therapy. Several proteins produced by bacteria after DNA recombination are presently undergoing clinical trials while others are already being produced on a large scale. Thus, in the area of recombinant DNA techniques the transition from the research laboratory to industrial exploitation has occurred much faster than was anticipated several years ago. The methods, possibilities and problems encountered in the synthesis of peptide hormones by bacteria after DNA recombination are outlined, using insulin, somatostatin, and growth hormone as examples. Great emphasis is placed on the molecular biological aspects of this approach. |
